EGFR Tyrosine Kinase Inhibitors (EGFR-TKIs) are first-line therapy for patients with EGFR-activating-mutations NSCLC, and they include gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.